Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune (NASDAQ:REPL) received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma treatment.
The FDA determined that the IGNYTE trial does not provide substantial evidence of effectiveness and cannot be adequately interpreted due to patient population heterogeneity. The agency also raised concerns about the confirmatory trial study design. While no safety issues were identified, the FDA cannot approve the application in its present form.
Replimune plans to request a Type A meeting within 30 days to discuss a path forward for RP1's accelerated approval, noting that without approval, further development for advanced cancer patients may not be viable.
Replimune (NASDAQ:REPL) ha ricevuto una Lettera di Risposta Completa (CRL) dalla FDA riguardante la sua Domanda di Licenza Biologica (BLA) per RP1 in combinazione con nivolumab per il trattamento del melanoma avanzato.
La FDA ha stabilito che lo studio IGNYTE non fornisce prove sostanziali di efficacia e non pu貌 essere adeguatamente interpretato a causa dell'eterogeneit脿 della popolazione di pazienti. L'agenzia ha inoltre sollevato preoccupazioni riguardo al disegno dello studio di conferma. Pur non avendo identificato problemi di sicurezza, la FDA non pu貌 approvare la domanda nella sua forma attuale.
Replimune intende richiedere un incontro di tipo A entro 30 giorni per discutere un percorso da seguire per l'approvazione accelerata di RP1, sottolineando che senza l'approvazione lo sviluppo ulteriore per i pazienti con cancro avanzato potrebbe non essere fattibile.
Replimune (NASDAQ:REPL) recibi贸 una Carta de Respuesta Completa (CRL) de la FDA respecto a su Solicitud de Licencia Biol贸gica (BLA) para RP1 en combinaci贸n con nivolumab para el tratamiento del melanoma avanzado.
La FDA determin贸 que el ensayo IGNYTE no proporciona evidencia sustancial de efectividad y no puede interpretarse adecuadamente debido a la heterogeneidad de la poblaci贸n de pacientes. La agencia tambi茅n expres贸 preocupaciones sobre el dise帽o del estudio confirmatorio. Aunque no se identificaron problemas de seguridad, la FDA no puede aprobar la solicitud en su forma actual.
Replimune planea solicitar una reuni贸n Tipo A dentro de 30 d铆as para discutir un camino a seguir para la aprobaci贸n acelerada de RP1, se帽alando que sin la aprobaci贸n, el desarrollo adicional para pacientes con c谩ncer avanzado podr铆a no ser viable.
Replimune (NASDAQ:REPL)鞚� 歆勴枆靹� 頋戩儔膦� 旃橂毳� 鞙勴暅 RP1瓿� 雼堧臣耄 氤戩毄鞐� 雽�頃� 靸濍頃欖爜 鞝滌牅 項堦皜 鞁犾箔靹�(BLA)鞐� 雽�頃� FDA搿滊秬韯� 鞕勳爠鞚戨嫷靹�(CRL)毳� 氚涭晿鞀惦媹雼�.
贵顿础电� IGNYTE 鞛勳儊鞁滍棙鞚� 須臣鞐� 雽�頃� 於╇秳頃� 歃濌卑毳� 鞝滉车頃橃 氇豁晿氅� 頇橃瀽 歆戨嫧鞚� 鞚挫靹膘溂搿� 鞚疙暣 鞝侅爤頌� 頃挫劃霅� 靾� 鞐嗠嫟瓿� 韺愲嫧頄堨姷雼堧嫟. 霕愴暅 頇曥澑 鞛勳儊鞁滍棙 靹り硠鞐� 雽�頃� 鞖半牑霃� 鞝滉赴頄堨姷雼堧嫟. 鞎堨爠靹� 氍胳牅電� 氚滉铂霅橃 鞎婌晿鞙茧倶, 順� 靸來儨搿滊姅 鞀轨澑鞚� 頃� 靾� 鞐嗠嫟瓿� 氚濏様鞀惦媹雼�.
Replimune鞚� 30鞚� 鞚措偞鞐� Type A 氙疙寘鞚� 鞖旍箔頃橃棳 RP1鞚� 臧�靻� 鞀轨澑 歆勴枆 氚╈晥鞚� 雲检潣頃� 瓿勴殟鞚措┌, 鞀轨澑鞚� 鞐嗢溂氅� 歆勴枆靹� 鞎� 頇橃瀽鞐� 雽�頃� 於旉皜 臧滊皽鞚� 鞏措牑鞖� 靾� 鞛堨潓鞚� 鞏戈笁頄堨姷雼堧嫟.
Replimune (NASDAQ:REPL) a re莽u une lettre de r茅ponse compl猫te (CRL) de la FDA concernant sa demande d'autorisation biologique (BLA) pour RP1 en association avec le nivolumab pour le traitement du m茅lanome avanc茅.
La FDA a d茅termin茅 que l'essai IGNYTE ne fournit pas de preuves substantielles d'efficacit茅 et ne peut 锚tre interpr茅t茅 de mani猫re ad茅quate en raison de l'h茅t茅rog茅n茅it茅 de la population de patients. L'agence a 茅galement soulev茅 des pr茅occupations concernant le plan d'茅tude de l'essai confirmatoire. Bien qu'aucun probl猫me de s茅curit茅 n'ait 茅t茅 identifi茅, la FDA ne peut approuver la demande sous sa forme actuelle.
Replimune pr茅voit de demander une r茅union de type A dans les 30 jours afin de discuter d'une voie 脿 suivre pour l'approbation acc茅l茅r茅e de RP1, soulignant que sans approbation, le d茅veloppement ult茅rieur pour les patients atteints de cancer avanc茅 pourrait ne pas 锚tre viable.
Replimune (NASDAQ:REPL) erhielt ein vollst盲ndiges Antwortschreiben (CRL) von der FDA bez眉glich seines Biologics License Application (BLA) f眉r RP1 in Kombination mit Nivolumab zur Behandlung von fortgeschrittenem Melanom.
Die FDA stellte fest, dass die IGNYTE-Studie keine ausreichenden Wirksamkeitsnachweise liefert und aufgrund der Heterogenit盲t der Patientenpopulation nicht angemessen interpretiert werden kann. Die Beh枚rde 盲u脽erte au脽erdem Bedenken zum Studiendesign der Best盲tigungsstudie. Obwohl keine Sicherheitsbedenken festgestellt wurden, kann die FDA den Antrag in der aktuellen Form nicht genehmigen.
Replimune plant, innerhalb von 30 Tagen ein Type-A-Meeting anzufordern, um den weiteren Weg f眉r die beschleunigte Zulassung von RP1 zu besprechen, und weist darauf hin, dass ohne Zulassung eine weitere Entwicklung f眉r Patienten mit fortgeschrittenem Krebs m枚glicherweise nicht machbar ist.
- No safety issues were identified by the FDA
- Company expects Type A meeting to be granted within 30 days
- FDA rejected the BLA for RP1 in its current form
- IGNYTE trial deemed inadequate for effectiveness evidence
- Issues with confirmatory trial study design identified
- Development may not be viable without accelerated approval
- FDA concerns were not raised during mid- and late-cycle reviews
Insights
FDA's Complete Response Letter to Replimune's melanoma therapy represents a significant regulatory setback that threatens the drug's development viability.
The FDA's issuance of a Complete Response Letter (CRL) for Replimune's RP1 (vusolimogene oderparepvec) represents a substantial regulatory setback. The agency's determination that the IGNYTE trial fails to constitute an adequate and well-controlled investigation delivering substantial evidence of effectiveness is particularly concerning. The FDA specifically cited patient population heterogeneity as rendering the trial results difficult to interpret properly.
This rejection comes despite the therapy previously receiving breakthrough designation, suggesting the FDA had initially recognized its potential for addressing an unmet need in advanced melanoma treatment. Importantly, while efficacy evidence and trial design were questioned, the FDA raised no safety concerns, which preserves one crucial aspect of the drug's profile.
The company's plan to request a Type A meeting with the FDA indicates they're pursuing the highest-priority consultation available, typically granted within 30 days. However, the CEO's statement that issues in the CRL weren't raised during mid- and late-cycle reviews signals a potential breakdown in communication during the review process. Most concerning is the company's assertion that without timely accelerated approval, further development of RP1 for advanced cancer patients with limited options "will not be viable" - language that suggests this setback could threaten the entire development program rather than merely delay it.
For a clinical-stage biotech without marketed products, this regulatory roadblock represents a critical challenge to its lead program's viability and potentially its development timeline.
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.聽(NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. Furthermore, the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population. The CRL also states that there are items related to the confirmatory trial study design which need to be addressed, including contribution of components. Importantly, no safety issues were raised.
The Company will request a Type A meeting and expects it will be granted within 30 days. Replimune plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1 without which the development of RP1 for advanced cancer patients with limited options will not be viable.
鈥淲e are surprised by this FDA decision and disappointed for advanced melanoma patients who have limited treatment options as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data,鈥� said Sushil Patel, Ph.D., Chief Executive Officer, Replimune. 鈥淭he issues highlighted in the CRL were not raised by the agency during the mid- and late-cycle reviews. Additionally, we had also aligned on the design of the confirmatory study. We strongly believe that RP1 in combination with nivolumab can bring substantial benefit to advanced melanoma patients.鈥�
础产辞耻迟听搁笔1
RP1聽(vusolimogene oderparepvec) is Replimune鈥檚 lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
础产辞耻迟听搁别辫濒颈尘耻苍别听
Replimune Group, Inc., headquartered in聽Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune鈥檚 proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit聽.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as 鈥渃ould,鈥� 鈥渆xpects,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥減lans,鈥� 鈥減otential,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the聽Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
FAQ
What was the FDA's decision on Replimune's (REPL) RP1 BLA for melanoma treatment?
Why did the FDA reject Replimune's (REPL) RP1 melanoma treatment application?
Were there any safety concerns in Replimune's (REPL) RP1 melanoma treatment?
What are Replimune's (REPL) next steps after receiving the FDA Complete Response Letter?
What is the impact of the FDA rejection on Replimune's (REPL) RP1 development?
